Letrozole 25

ACTIVE HALF-LIFE 2-3 days
CLASSIFICATION Non-steroidal aromatase inhibitor
DOSAGE 0.5-1 mg over 1 to 3 days
ACNE None
WATER RETENTION None
HBR Not applicable
HEPATOTOXICITY None
AROMATIZATION None
MANUFACTURER Hilma Biocare
LAB TEST Refer to Documentation
WAREHOUSE EU Warehouse 3
SUBSTANCE Letrozole

Letrozole is a revolutionary antitumor medication classified as a non-steroidal selective aromatase inhibitor. Originally designed to combat breast cancer, it is also a favored choice in post-menopausal therapy for women. Athletes have embraced Letrozole for its powerful anti-estrogenic properties, which contribute to improved muscle definition and performance. Remarkably, Letrozole is up to five times more effective than Anastrozole (Arimidex) in reducing the adverse effects often associated with anabolic steroid use, making it a game-changer in estrogen management.

By utilizing Letrozole, athletes can dramatically lower their estrogen levels, thereby preventing aromatization and its potential negative consequences.

While Letrozole is highly effective, users may experience some side effects, including skin rashes, nausea, abdominal discomfort, fatigue, dizziness, headaches, increased levels of low-density cholesterol, and elevated liver enzymes.

Before starting Letrozole, it is recommended to undergo preliminary blood tests. This proactive step can lead to a significant reduction in estradiol levels, thereby enhancing the overall effectiveness of your cycle. Letrozole is particularly known for its role as an anti-estrogenic agent, making it a staple during post-cycle therapy (PCT).

Letrozole shines during PCT, but it can also be effectively stacked with clomiphene or other steroids to optimize your cycle results.